Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196384 | 0.94 | PDE5A (0.36) | PDE5ATYMPMBOAT4PYCR1PDE2A | |
| SCHEMBL2197113 | 0.91 | PDE5A (0.35) | PDE5ATYMPMBOAT4PYCR1PDE2A | |
| SCHEMBL2195103 | 0.90 | PDE2A (0.35) | PDE5ATYMPPDE2ASIGMAR1ALKBH3 | |
| SCHEMBL2195783 | 0.90 | PDE2A (0.36) | PDE5ATYMPMBOAT4PYCR1PDE2A | |
| SCHEMBL2194836 | 0.90 | PDE2A (0.35) | PDE5ATYMPPDE2ASIGMAR1ALKBH3 | |
| SCHEMBL2193206 | 0.89 | NR1H2 (0.36) | PDE5ATYMPMBOAT4PDE2A | |
| SCHEMBL2194436 | 0.87 | BCHE (0.34) | TYMPPYCR1ALKBH3 | |
| SCHEMBL2196147 | 0.81 | PDE5A (0.41) | PDE5ATYMPMBOAT4PDE2ASIGMAR1 | |
| SCHEMBL2198379 | 0.81 | PDE5A (0.43) | PDE5ATYMPSIGMAR1AADAT | |
| SCHEMBL2194720 | 0.81 | PDE5A (0.43) | PDE5ATYMPSIGMAR1AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980875-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-17 | — | — | US | claimed |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-19 | — | — | US | claimed |
| US-8481522-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-07-09 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | PDE5A 4509/4885TYMP 1033/4885IDO1 836/4885 |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | PDE5A 4509/4885TYMP 1033/4885IDO1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.